GTHX stock forecast
Our latest prediction for G1 Therapeutics, Inc.'s stock price was made on the Sept. 17, 2018 when the stock price was at 66.40$.
In the short term (2weeks), GTHX's stock price should underperform the market by -1.45%. During that period the price should oscillate between -8.48% and +9.02%.
In the medium term (3months), GTHX's stock price should underperform the market by -2.73%. During that period the price should oscillate between -20.41% and +25.12%.Get email alerts
Create a solid portfolio with GTHX
About G1 Therapeutics, Inc.
G1 Therapeutics, Inc. engages in the development of small molecule therapeutics for the treatment of patients with cancer. Its products pipeline includes trilaciclib, rintodestrant, and lerociclib. The company was founded by Kwok-Kin Wong and Norman E. Sharpless on May 19, 2008 and is headquartered in Research Triangle Park, NC.
At the moment the company generates 2M USD in revenues.
On its last earning announcement, the company reported a loss of -3.46$ per share.
The book value per share is 5.28$
Three months stock forecastSept. 17, 2018
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|